# Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

> **NCT06572553** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Age-Related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT06572553
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572553, "Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06572553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*